Explore more price target data and ratings for Integra LifeSciences Holdings Corporation on the Forecasts tab, and track all previous and future analyst recommendations for Integra LifeSciences Holdings Corporation in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 20…
Q2 2026 revenue reached $419 million with adjusted EPS up 24% year-over-year, exceeding guidance due to operational execution and tariff favorability. Full-year organic growth and EPS guidance were reaffirmed, with key milestones advanced in product relaunches and operational improvements.Based on…
Q2 2026 revenue grew 0.8% year-over-year to $418.8 million, with adjusted EPS rising to $0.56. Specialty Surgery saw modest growth, while Tissue Reconstruction declined. Full-year guidance was updated for FX, with organic growth and adjusted EPS targets reaffirmed.Original document: Integra LifeSci…
Integra LifeSciences reported second-quarter 2026 results with total revenue of $418.8 million and GAAP net income of $4.5 million (diluted EPS $0.06). Adjusted diluted earnings per share were $0.56 and adjusted EBITDA was $78.4 million for the quarter. The company reaffirmed full-year 2026 organic…
Medical device company Integra LifeSciences NASDAQ:IARTwill be announcing earnings results this Wednesday morning. Here’s what to look for.Integra LifeSciences beat analysts’ revenue expectations last quarter, reporting revenues of $391.9 million, up 2.4% year on year. It was a strong quarter for t…
What Happened? Shares of medical device company Integra LifeSciences NASDAQ:IARTjumped 4.3% in the afternoon session after BMO Capital initiated coverage on the stock with a "Market Perform" rating and a $19 price target.The firm noted that the return of Essig as chief executive officer provides op…
